| Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169) |
|---|
| 05/16/2001 | EP1098886A1 Phthalazine derivatives as phosphodiesterase 4 inhibitors |
| 05/16/2001 | EP1098885A1 Imidazole compounds and their use as adenosine deaminase inhibitors |
| 05/16/2001 | EP1098884A1 Il-8 receptor antagonists |
| 05/16/2001 | EP1098873A1 Alpha-(2-hydroxyphenyl)nitrone compounds, pharmaceutical compositons containing the same and their use for treating inflammation |
| 05/16/2001 | EP1098659A2 Libraries of polyhydroxamates and their analogs |
| 05/16/2001 | EP0996437B1 Semisolid pharmaceutical formulation containing dexketoprofen trometamol |
| 05/16/2001 | EP0941089B1 Use of anti-microtubule agents for treating or preventing multiple sclerosis |
| 05/16/2001 | EP0859766B1 Chiral methyl phenyl oxazolidinones |
| 05/16/2001 | CN1295614A Modulator for function of receptor of TNF/NGF receptor family and other protein |
| 05/16/2001 | CN1295578A Pharmaceuticals for imaging of angiogenic disorders |
| 05/16/2001 | CN1295571A PDE IV inhibiting pyridine derivatives |
| 05/16/2001 | CN1295565A Barbituric acid derivative and preventive and therapeutic agent for bone and cartilage containing the same |
| 05/16/2001 | CN1295483A Gelling ophthalmic composition containing xanthan gum |
| 05/16/2001 | CN1295482A Antagonists of the inflammatory mediator oncostatin M (OSM) |
| 05/16/2001 | CN1295478A Novel galanic formulation of meloxicam for oral administration |
| 05/16/2001 | CN1295471A Antagonists for treatment of CD11/CD18 adhesion receptor mediated disorders |
| 05/16/2001 | CN1295462A Peroral active agent suspension |
| 05/16/2001 | CN1295461A Anti-enzyme composition comprising ethylenediamine disuccinic acid |
| 05/16/2001 | CN1295065A Phenyl heterocyclic compound used as epoxy enzyme -2 inhibitor |
| 05/16/2001 | CN1294916A Medicated wine for treating rheumatism and pain bones and muscles and its preparation |
| 05/16/2001 | CN1065764C Quickly-acting antalgesic liniment and its preparing process |
| 05/15/2001 | US6232441 PIGR-1, a member of immunoglobulin gene superfamily |
| 05/15/2001 | US6232342 Protease inhibitors |
| 05/15/2001 | US6232321 Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
| 05/15/2001 | US6232315 Method for treating inflammatory diseases by administering a thrombin inhibitor |
| 05/15/2001 | US6232308 Useful for inhibiting bone resorption, treating and preventing osteoporosis, inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, and angiogenesis |
| 05/15/2001 | US6232305 Substituted amino bicyclic-β-lactam penam and cepham derivatives as cysteine protease inhibitors |
| 05/15/2001 | US6232077 Genetic engineering and expression; cancer diagnosis |
| 05/15/2001 | US6231886 Methods of providing sustained treatment with opioids |
| 05/15/2001 | US6231594 Method of controlling body temperature while reducing shivering |
| 05/15/2001 | CA2180011C Botulinum toxins for treating sweating |
| 05/15/2001 | CA2041638C Recombinant polynucleotide constructs suitable for providing secretion of pai-2 |
| 05/10/2001 | WO2001033221A1 Axor35, a g-protein coupled receptor |
| 05/10/2001 | WO2001032926A2 Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same |
| 05/10/2001 | WO2001032910A2 27 human secreted proteins |
| 05/10/2001 | WO2001032888A2 Human transferase molecules |
| 05/10/2001 | WO2001032877A2 CpG RECEPTOR (CpG-R) AND METHODS RELATING THERETO |
| 05/10/2001 | WO2001032867A1 Polypeptides with expanded primary signalling motifs |
| 05/10/2001 | WO2001032866A2 Hybrid adaptor receptors |
| 05/10/2001 | WO2001032709A2 Polypeptides with non-natural primary signalling motifs |
| 05/10/2001 | WO2001032696A2 Traf family proteins |
| 05/10/2001 | WO2001032687A1 10 human secreted proteins |
| 05/10/2001 | WO2001032680A2 18-nor-steroids as selectively active estrogens |
| 05/10/2001 | WO2001032677A1 Uteroglobin-like polynucleotides, polypeptides, and antibodies |
| 05/10/2001 | WO2001032675A1 32 human secreted proteins |
| 05/10/2001 | WO2001032674A1 26 human secreted proteins |
| 05/10/2001 | WO2001032667A1 Ether-type gla-60 analogues |
| 05/10/2001 | WO2001032663A2 Pyrazolecarboxylic acid tricyclic derivatives, preparation and pharmaceutical compositions containing same |
| 05/10/2001 | WO2001032658A1 Polyazanaphthalene compound and medicinal use thereof |
| 05/10/2001 | WO2001032656A1 Polymorphic form of a tachykinin receptor antagonist |
| 05/10/2001 | WO2001032654A2 Novel heterocyclic compounds and their use as medicines |
| 05/10/2001 | WO2001032653A1 Heterocyclic substituted pyrazolones |
| 05/10/2001 | WO2001032651A1 Quinazoline derivatives as vegf inhibitors |
| 05/10/2001 | WO2001032649A1 Arylalkane, arylalkene and aryl azaalkane, medicaments containing said compounds and method for the production thereof |
| 05/10/2001 | WO2001032648A1 Novel cyclopropanes as cgrp antagonists, medicaments containing said compounds and method for the production thereof |
| 05/10/2001 | WO2001032629A1 1-benzylpyrazoles-3-carboxylic acid tricyclic derivatives as cannabinoid receptor antagonists |
| 05/10/2001 | WO2001032621A1 Novel indole derivatives and drugs containing the same as the active ingredient |
| 05/10/2001 | WO2001032618A1 Pyrrole derivatives as phosphodiesterase vii inhibitors |
| 05/10/2001 | WO2001032614A2 Novel genes tzap7/a, tzap7/b and tzap7 involved in t cell activation and uses thereof |
| 05/10/2001 | WO2001032611A1 N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them |
| 05/10/2001 | WO2001032606A1 Compounds having mif antagonist activity |
| 05/10/2001 | WO2001032222A1 Selective toxin expression in angiogenic endothelial cells |
| 05/10/2001 | WO2001032216A2 Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance |
| 05/10/2001 | WO2001032179A1 8-aza-bicyclo[3.2.1]octane nmda/nr2b antagonists |
| 05/10/2001 | WO2001032176A1 Beta-carboline derivatives for use as analgesics |
| 05/10/2001 | WO2001032175A1 Isoxazole derivatives to be used as phosphodiesterase vii inhibitors |
| 05/10/2001 | WO2001032169A1 Agonists specific for the peripheral cannabinoid receptor |
| 05/10/2001 | WO2001032166A1 NEW COMBINATION COMPRISING A β2-ADRENORECEPTOR AGONIST AND A LEUKOTRIENE RECEPTOR ANTAGONIST |
| 05/10/2001 | WO2001032165A1 Method for administering a phosphodiesterase 4 inhibitor |
| 05/10/2001 | WO2001032163A1 NEW COMBINATION COMPRISING A BETA 2 (β)2 ADRENO RECEPTOR AGONIST AND A LENKOTRIENE RECEPTOR ANTAGONIST |
| 05/10/2001 | WO2001032144A1 Dry powder compositions having improved dispersivity |
| 05/10/2001 | WO2001032127A2 Method and compositions for treating pulmonary diseases |
| 05/10/2001 | WO2001017959A3 Vitronectin receptor antagonists |
| 05/10/2001 | WO2001015719A3 Treatment of conjunctivitis |
| 05/10/2001 | WO2001012175A8 Uses compositions for treating or preventing sleep disturbances using very low doses of cyclobenzaprine |
| 05/10/2001 | WO2001005974A3 The il-1l1 gene and polypeptide products |
| 05/10/2001 | WO2000077207A3 Nucleic acid encoding proteins involved in protein degradation, products and methods related thereto |
| 05/10/2001 | WO2000063241A3 Methods and compositions for modulating an immune response |
| 05/10/2001 | WO2000033888A9 Prodrug compounds and process for preparation thereof |
| 05/10/2001 | DE19953414A1 Imidazopyridinderivate als Phospodiesterase VII-Hemmer Imidazopyridine derivatives as phosphodiesterase VII inhibitor |
| 05/10/2001 | DE19953025A1 Pyrrolderivate als Phosphodiesterase VII-Hemmer Pyrrole derivatives as phosphodiesterase VII inhibitor |
| 05/10/2001 | DE19953024A1 Isoxazolderivate als Phosphodiesterase VII-Hemmer Isoxazole derivatives as phosphodiesterase VII inhibitor |
| 05/10/2001 | CA2389807A1 Heterocyclic substituted pyrazolones |
| 05/10/2001 | CA2389765A1 Cpg receptor (cpg-r) and methods relating thereto |
| 05/10/2001 | CA2389751A1 Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same |
| 05/10/2001 | CA2389690A1 Selective toxin expression in angiogenic endothelial cells |
| 05/10/2001 | CA2389661A1 Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance |
| 05/10/2001 | CA2389415A1 Novel genes tzap7/a, tzap7/b and tzap7 involved in t cell activation and uses thereof |
| 05/10/2001 | CA2389293A1 Method for administering a phosphodiesterase 4 inhibitor |
| 05/10/2001 | CA2389229A1 Compounds having mif antagonist activity |
| 05/10/2001 | CA2388822A1 27 human secreted proteins |
| 05/10/2001 | CA2388657A1 New combination comprising a beta 2 (.beta.)2 adreno receptor agonist and a leukotriene receptor antagonist |
| 05/10/2001 | CA2388333A1 Method and compositions for treating pulmonary diseases |
| 05/10/2001 | CA2388202A1 Polymorphic form of a tachykinin receptor antagonist |
| 05/10/2001 | CA2388171A1 8-aza-bicyclo[3.2.1]octane nmda/nr2b antagonists |
| 05/10/2001 | CA2387801A1 Uteroglobin-like polynucleotides, polypeptides, and antibodies |
| 05/10/2001 | CA2387785A1 Human transferase molecules |
| 05/10/2001 | CA2387754A1 10 human secreted proteins |
| 05/10/2001 | CA2387613A1 Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them |
| 05/10/2001 | CA2387136A1 26 human secreted proteins |